- Home
- JBGS vs PHAR Comparison
JBGS vs PHAR Comparison
Compare JBGS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBGS | PHAR |
|---|---|---|
| Founded | 2016 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JBGS | PHAR |
|---|---|---|
| Price | $14.27 | $14.67 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $17.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 488.6K | 17.8K |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $498,598,000.00 | N/A |
| Revenue This Year | N/A | $27.92 |
| Revenue Next Year | N/A | $8.86 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.28 | $7.50 |
| 52 Week High | $24.30 | $21.34 |
Technical Indicators
Market Signals| Indicator | JBGS | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 26.34 | 37.40 |
| Support Level | $14.21 | $12.98 |
| Resistance Level | $18.70 | $15.21 |
| Average True Range (ATR) | 0.46 | 0.67 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 3.72 | 1.77 |
Price Performance
Historical ComparisonAbout JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.